# Rivaroxaban Once Daily Versus Dose-adjusted Vitamin K Antagonist on the Biomarkers in Acute Decompensated Heart Failure and Atrial Fibrillation (ROAD HF-AF)

> **NCT03490994** · PHASE4 · UNKNOWN · sponsor: **Yonsei University** · enrollment: 150 (estimated)

## Conditions studied

- Acute Heart Failure

## Interventions

- **DRUG:** Rivaroxaban
- **DRUG:** Warfarin + LMWH

## Key facts

- **NCT ID:** NCT03490994
- **Lead sponsor:** Yonsei University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-04-10
- **Primary completion:** 2019-09
- **Final completion:** 2020-01
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2019-01-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03490994

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03490994, "Rivaroxaban Once Daily Versus Dose-adjusted Vitamin K Antagonist on the Biomarkers in Acute Decompensated Heart Failure and Atrial Fibrillation (ROAD HF-AF)". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03490994. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*